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Abstract
Background: Colorectal cancer (CRC) mortality has declined in the United States, in part because of advances in treatment. 
Few studies have evaluated the adoption of therapies and temporal changes in patterns of care.
Methods: Patients age 20 years and older diagnosed with stages II/III CRC were randomly sampled from the population-
based Surveillance, Epidemiology, and End Results (SEER) program in 1990–1991, 1995, 2000, 2005, and 2010 (n = 7057). 
Therapy was obtained from medical records and physician verification. We described the receipt of chemotherapy and 
radiation therapy. Log-binomial regression was used to examine factors associated with therapy. All statistical tests were 
two-sided.
Results: Chemotherapy receipt among colon cancer patients increased from 1990 (stage II: 22.5%; stage III: 56.3%) to 2005 
(stage II: 32.1%; stage III: 72.4%) and declined slightly in 2010 (stage II: 29.3%; stage III: 66.4%). Stage III colon cancer patients 
who were older (vs <55 years, 75–79 years: risk ratio [RR] 0.81, 95% confidence interval [CI] = 0.71 to 0.91; ≥80 years: RR = 0.37, 
95% CI = 0.28 to 0.47) or had a comorbidity score of 2 or higher (vs 0, RR = 0.56, 95% CI = 0.35 to 0.87) received chemotherapy 
less often. Receipt of radiation therapy by rectal cancer patients increased across all years from 45.5% to 66.1%. Increasing 
age (vs <55 years, 75–79 years: RR = 0.59, 95% CI = 0.47 to 0.74; ≥80 years: RR = 0.33, 95% CI = 0.25 to 0.45) was associated with 
lower chemoradiation use among stage II/III rectal cancer patients.
Conclusion: Our findings demonstrate increased adoption of chemotherapy and radiation therapy for colon and rectal 
cancer patients and differences in therapy by age, comorbidity, and diagnosis year. Increased receipt of these therapies in 
the community may further reduce CRC mortality.
The incidence and mortality of colorectal cancer (CRC) have 
continually declined in the United States over the past two dec-
ades. During the years 2001 to 2010, average annual mortality 
rates were 19.6 and 13.9 per 100 000 men and women, respec-
tively. Mortality rates have decreased by 3.0% per year in both 
men and women, and the overall five-year relative survival rate 
has increased from 49.8% in 1975–1977 to 66.1% in 2003–2009 (1). 
Much of the mortality decline has been attributed to screening 
and advances in treatment (2).
Adjuvant chemotherapy has gained attention as a critical 
advance in the treatment of colon cancer. Growing evidence 
suggests several adjuvant chemotherapy regimens markedly 
improve the overall and disease-free survival of patients with 
resectable stage III disease (3–8). In contrast, the use of adjuvant 
therapy for patients with stage II colon cancer remains contro-
versial. Clinical trial results are inconclusive, and many studies 
show no survival benefit for adjuvant chemotherapy over sur-
gery alone in stage II patients (9).











The use of preoperative radiation therapy has similarly been 
recognized as an important advance in the evolution of treatment 
for locally advanced rectal cancer (stages II and III) (10). Early ran-
domized trials showed the benefit of postoperative radiation in 
decreasing local recurrence (11,12), but later trials suggested that 
preoperative radiation therapy also decreases the risk of local 
recurrence compared with surgery alone (13,14). Although overall 
survival is similar between patients treated with preoperative and 
postoperative radiation, preoperative radiation is associated with 
greater improvements in local control, increased rates of sphinc-
ter preservation during surgery, and fewer treatment-induced 
toxicities (15–17). The addition of chemotherapy to preoperative 
radiation (ie, chemoradiation) has since been shown to further 
improve local control and enhance pathological response (18–20).
Few studies have examined the adoption of recommended 
therapies in community settings as evidence from clinical trials 
has changed. We aimed to describe receipt of adjuvant chemo-
therapy among patients diagnosed with stages II and III colon 
cancer and preoperative and/or postoperative radiation therapy 
among patients diagnosed with stages II and III rectal cancer. 
We also assessed the association of receipt of therapy with 
patient demographic and tumor characteristics.
Methods
Participants and Procedures
Patients were sampled from the National Cancer Institute’s 
(NCI’s) Surveillance, Epidemiology, and End Results (SEER) pro-
gram. SEER routinely collects information from hospitals, pathol-
ogy laboratories, surgical centers, and radiation facilities on 
patient demographics and tumor characteristics. Preoperative 
(neoadjuvant) and postoperative (adjuvant) therapies are often 
underreported in SEER; therefore, the NCI annually conducts 
patterns of care (POC) studies on a sample of patients with 
select cancers to assess the extent to which chemotherapy and 
radiation therapy are received in clinical practice (21,22).
Stages II and III CRC patients in participating SEER regis-
tries were eligible for POC studies in 1990–1991, 1995, 2000, 
2005, and 2010. Eligible patients were stratified within regis-
tries by tumor site (colon or rectum), and a random sample was 
taken from within each stratum. Beginning in 1995, there was 
oversampling by race/ethnicity to obtain more stable estimates 
for these subgroups. Patients were sampled according to the 
staging scheme used by SEER in each study year. In 1990 or 
1991, 1995, and 2000, patients were sampled based on Extent 
of Disease (EOD) 10 coding, and in 2005 and 2010 patients were 
sampled based on Collaborative Staging (CS) coding. EOD and 
CS coding record the farthest extent of disease based on the 
combined clinical and pathological assessment. Clinical infor-
mation takes priority when a patient is treated with preopera-
tive therapy; otherwise, pathological information takes priority. 
TNM staging was derived by mapping T and N status from EOD 
and CS coding. Stage II included T3 or T4 tumors with no posi-
tive regional lymph nodes, and stage III included any T1 to T4 
tumors with regional lymph node involvement. These stage 
definitions also correspond approximately to stage B2 and C of 
the Aster-Coller modification of Duke’s original staging system.
Patients were ineligible if they were younger than age 
20 years, previously diagnosed with cancer (excluding nonmela-
noma skin cancer), diagnosed at autopsy or on death certificate 
only, or diagnosed with a synchronous cancer. Patients with 
tumors in the appendix (n = 4) or who did not undergo cancer-
directed surgery (n = 171) were further excluded.
Patients’ medical records were abstracted for treatment 
information, including receipt of specific chemotherapy agents, 
radiation therapy, and dates of treatment following diagnosis. 
Because chemotherapy and radiation therapy are often given 
outside of the hospital setting and SEER data is primarily hospi-
tal-based, the treating physician was contacted to verify therapy 
received or recommended. Treating physicians were also asked 
to provide names and addresses of other physicians who may 
have treated the patient, who were subsequently contacted 
for treatment information. Doctor verification substantially 
improves completeness of chemotherapy ascertainment or con-
firms that no chemotherapy or radiation was given. Physician 
responses were received on more than 85% of sampled patients.
Comorbid conditions at the time of hospitalization for the 
most definitive treatment, usually surgery, were abstracted from 
the medical record. Patient comorbidity was assessed using the 
Charlson comorbidity index (23).
Analysis
Weighted proportions and means were used to examine trends in 
the receipt of adjuvant chemotherapy among stages II and III colon 
cancer patients and preoperative or postoperative radiation among 
stages II and III rectal cancer patients. We considered patients 
who received therapy or were recommended but it was unknown 
whether they received therapy as having received treatment in the 
analysis. Patients who refused chemotherapy (n = 148) or radiation 
therapy (n = 26) were not considered to have received therapy. We 
also examined the proportion of patients who received common 
chemotherapy agents and combination chemotherapy regimens. 
Although there is a lack of consensus on the use of chemotherapy 
for stage II colon cancer, we included these patients in select tables. 
In addition, we examined the proportion of rectal cancer patients 
who received any chemoradiation (ie, receipt of both chemother-
apy and radiation at any point during the course of treatment) and 
various combinations of multimodality therapy.
Proportions and means were calculated with stratum-spe-
cific sample weights to account for the complex survey design. 
The proportions reported are weighted to reflect the population 
from which the sample was drawn. Sample weights were calcu-
lated as the inverse of the sampling proportion for each sam-
pling stratum.
We used log-binomial regression models with stratum-spe-
cific sample weights to explore factors associated with receipt 
of adjuvant chemotherapy among stage III colon cancer patients 
and chemoradiation (preoperative or postoperative) among 
stages II and III rectal cancer patients. Sensitivity analyses con-
sidering differential registry participation by year and variation 
in the receipt of therapy by geographic region did not appre-
ciably affect the results (not shown); therefore, we report the 
results of the overall analysis. Adjusted associations between 
covariates and receipt of therapy are reported as risk ratios and 
95% confidence intervals.
Analyses were conducted using SAS version 9.3 (SAS Institute, 
Cary, NC) and SUDAAN version 11.0.1 (Research Triangle 
Institute, Raleigh, NC). All statistical tests were two-sided.
Results
Characteristics of the study population (n  =  7057) by year of 
diagnosis are shown in Table 1. Overall, 28.7% and 65.4% of stage 
II and III colon cancer patients received adjuvant chemother-
apy, respectively (Table 2). Chemotherapy use increased among 
both stages from 1990 or 1991 (stage II: 22.5%; stage III: 56.3%) 











to 2005 (stage II: 32.1%; stage III: 72.4%) and slightly decreased 
in 2010 (stage II: 29.3%; stage III: 66.4%). Receipt differed by age 
at diagnosis among stage II patients, with increases in receipt 
of therapy between 1990 or 1991 and 2000 in the 55 to 64 and 65 
to 74 year age groups (Supplementary Figure 1, available online). 
There were also differences in receipt of adjuvant chemotherapy 













No. (wt %) No. (wt %) No. (wt %) No. (wt %) No. (wt %)
Sociodemographic characteristics
Sex
 Male 1087 (49.5) 541 (48.2) 447 (49.9) 834 (50.5) 731 (51.1)
 Female 926 (50.5) 573 (51.8) 429 (50.1) 768 (49.5) 721 (48.9)
Age at diagnosis, mean (SD), y 70.0 (0.30) 69.2 (0.59) 69.3 (0.60) 67.2 (0.61) 66.5 (0.60)
 <55 254 (10.4) 186 (13.8) 188 (13.6) 419 (19.9) 395 (21.0)
 55–64 406 (18.0) 246 (19.0) 187 (20.8) 366 (20.4) 345 (23.7)
 65–74 671 (33.8) 341 (30.0) 237 (27.0) 369 (23.9) 339 (21.5)
 75–79 287 (15.3) 149 (15.4) 105 (13.0) 185 (14.7) 144 (11.4)
 ≥80 395 (22.5) 192 (21.9) 159 (25.6) 263 (21.1) 229 (22.4)
Race/ethnicity
 White non-Hispanic 1731 (87.6) 564 (81.1) 329 (73.2) 568 (70.7) 466 (68.0)
 Black non-Hispanic 163 (7.3) 273 (10.8) 197 (9.1) 351 (9.9) 356 (9.8)
 Hispanic 64 (2.7) 277 (8.1) 168 (8.1) 324 (10.3) 301 (12.7)
 Other 55 (2.3) 0 182 (9.6) 359 (9.0) 329 (9.4)
Health insurance
 Private/HMO/VA/Other 1520 (75.1) 782 (74.6) 539 (66.2) 1047 (73.0) 910 (65.6)
 Medicaid 74 (3.5) 115 (6.2) 137 (9.9) 246 (10.2) 310 (16.8)
 Medicare 315 (17.1) 149 (13.0) 147 (19.5) 228 (14.5) 147 (11.9)
 None 31 (1.4) 38 (2.8) 32 (2.2) 65 (1.7) 69 (3.9)
 Unknown 73 (2.9) 30 (3.3) 21 (2.2) 16 (0.6) 16 (1.8)
Marital status
 Married 1232 (57.7) 611 (55.1) 477 (55.0) 876 (50.6) 749 (53.2)
 Not married† 744 (40.3) 485 (43.1) 368 (42.0) 692 (47.4) 639 (42.5)
 Unknown 37 (2.0) 18 (1.8) 31 (3.0) 34 (1.9) 64 (4.3)
Comorbidity score
 0 1507 (74.1) 776 (70.6) 666 (74.0) 1132 (70.1) 963 (66.7)
 1 408 (20.9) 274 (25.0) 163 (21.0) 373 (23.5) 386 (26.2)
 ≥2 98 (5.0) 64 (4.5) 47 (5.0) 97 (6.4) 103 (7.1)
Tumor characteristics
Site
 Colon 1080 (77.4) 631 (77.6) 494 (75.2) 920 (72.8) 740 (71.4)
 Rectum‡ 933 (22.6) 483 (22.4) 382 (24.8) 682 (27.2) 712 (28.6)
Stage§
 II 974 (58.7) 564 (55.5) 372 (40.7) 829 (50.9) 723 (49.1)
 III 1039 (41.3) 550 (44.5) 504 (59.3) 773 (49.1) 729 (50.9)
Number of positive lymph nodes 
(stage III only), mean (SD)
3.2 (0.10) 3.6 (0.23) 3.6 (0.24) 3.5 (0.19) 3.2 (0.19)
Histologic grade
 Well differentiated 176 (8.6) 55 (6.9) 43 (5.2) 94 (8.5) 70 (4.8)
 Moderately differentiated 1328 (66.3) 796 (67.0) 599 (65.7) 1133 (66.0) 1037 (71.5)
 Poorly differentiated 354 (17.1) 217 (21.9) 194 (25.0) 289 (21.6) 232 (17.2)
 Undifferentiated 17 (1.0) 8 (1.2) 8 (1.1) 20 (1.6) 46 (3.3)
 Unknown 138 (7.0) 38 (3.0) 32 (2.9) 66 (2.3) 63 (3.2)
Clinical trial participation
 No 1461 (75.6) 805 (76.5) 846 (96.1) 1471 (88.5) 1407 (96.4)
 Yes 165 (7.0) 49 (3.0) 20 (3.1) 76 (4.9) 11 (0.5)
 Unknown 387 (17.4) 260 (20.4) 10 (0.9) 55 (6.6) 34 (3.1)
 * Percentages and means weighted by sampling fraction. Missing or unknown values included in proportions. wt = weighted.
† Not married includes single, divorced, separated, and widowed. 
‡ Rectum includes tumors in the rectum or rectosigmoid junction. 
§ Patients diagnosed in 1990 or 1991, 1995, and 2000 were sampled based on Extent of Disease (EOD) 10 coding, and patients diagnosed in 2005 and 2010 were 
sampled based on Collaborative Staging (CS) coding. TNM staging was derived by mapping T and N status from EOD and CS coding. Stage II included T3 or T4 
tumors with no positive regional lymph nodes, and stage III included any T1 to T4 tumors with regional lymph node involvement. Stage definitions also correspond 
approximately to stage B2 and C of the Aster-Coller modification of Duke’s original staging system.











for stage III patients by age and comorbidity (Figure 1). Receipt 
was highest among younger age groups (age <55 years, 84.5%; 
age 55–64 years, 84.9%) and patients with a comorbidity score 
of 0 (68.5%). A substantially smaller proportion of patients over 
the age of 80  years received chemotherapy in all study years 
(Supplementary Figure 2, available online).
Among stage III patients who received chemotherapy, there 
was a rapid increase in the use of oxaliplatin (5.5% in 2000 to 
78.1% in 2010) and capecitabine (3.0% in 2000 to 23.6% in 2010), 
with a parallel decrease in the use of any 5-FU (98.8% in 1990 or 
1991 to 79.3% in 2010) (Table 3). The majority of patients diag-
nosed in 1990 or 1991 (56.4%) and 1995 (53.3%) received 5-FU 
and levamisole, whereas patients diagnosed in 2010 were pre-
dominantly treated with FOLFOX (72.6%). A growing number of 
patients were treated with capecitabine alone (12.1% in 2010) or 
in combination with oxaliplatin (ie, CapeOx) (4.3% in 2010).
The proportion of stages II and III rectal cancer patients who 
received any radiation therapy (preoperative or postoperative) 
increased from 45.5% in 1990 or 1991 to 66.1% in 2010 (Figure 2). 
Receipt of any radiation therapy was higher among younger 
patients (age <55  years, 74.4%) compared with older patients 
(age ≥80 years, 25.1%) and among patients with a comorbidity 
score of 0 (60.4%) compared with patients with a comorbidity 
score of 2 or higher (53.4%). During the study period, 31.6% of 
patients received postoperative radiation therapy and 27.3% 
received preoperative radiation (Table 4). Receipt of preoperative 
radiation substantially increased over time, from 2.8% in 1990 or 
1991 to 47.3% in 2010. The proportion of patients who received 
postoperative radiation increased from 1990 or 1991 (42.7%) to 
1995 (51.3%) and subsequently decreased through 2010 (18.8%).
Receipt of chemoradiation for rectal cancer increased from 
37.2% in 1990 or 1991 to 66.6% in 2010 (Supplementary Figure 3, 
Table 2. Proportion of stages II and III colon cancer patients who received adjuvant chemotherapy by stage at diagnosis (n = 3757)*
Characteristics
Proportion of patients receiving chemotherapy
Stage II (n = 1908) Stage III (n = 1849)
wt % 95 % CI wt % 95% CI
Overall 28.7 25.4 to 32.3 65.4 61.8 to 68.9
Year of diagnosis
 1990/1991 22.5 19.0 to 26.4 56.3 51.0 to 61.4
 1995 27.9 21.2 to 35.6 59.5 48.6 to 69.6
 2000 33.5 24.4 to 44.2 65.3 56.2 to 73.4
 2005 32.1 24.8 to 40.5 72.4 65.1 to 78.7
 2010 29.3 21.8 to 38.2 66.4 58.2 to 73.7
Age at diagnosis, y
 <55 59.5 48.6 to 69.5 84.5 78.6 to 89.0
 55–64 46.2 38.4 to 54.2 84.9 79.3 to 89.2
 65–74 29.9 23.9 to 36.6 72.9 65.4 to 79.3
 75–79 17.3 11.3 to 25.4 63.0 54.0 to 71.2
 ≥80 5.8 3.6 to 9.0 30.3 21.9 to 40.3
Race/ethnicity
 White non-Hispanic 28.1 23.9 to 32.6 65.5 60.8 to 70.0
 Black non-Hispanic 28.8 23.5 to 34.8 60.8 54.8 to 66.6
 Hispanic 34.4 27.3 to 42.3 65.0 54.7 to 74.1
 Other 29.8 23.0 to 37.6 71.0 62.1 to 78.6
Health insurance
 Private/HMO/VA/Other 31.2 26.9 to 35.7 67.0 62.7 to 71.1
 Medicaid 24.2 15.8 to 35.2 61.4 51.8 to 70.2
 Medicare 18.5 12.6 to 26.3 57.9 47.7 to 67.5
 None 43.3 28.0 to 60.0 73.6 55.2 to 86.3
 Unknown 39.9 19.8 to 64.2 76.0 50.6 to 90.7
Comorbidity score
 0 31.5 27.4 to 36.0 68.5 64.3 to 72.4
 1 23.1 17.2 to 30.4 64.0 56.5 to 70.9
 ≥2 16.8 7.2 to 34.2 33.6 22.0 to 47.6
Tumor extent
 T1-2 NA NA 76.9 66.9 to 84.5
 T3 24.8 21.7 to 28.3 65.4 61.4 to 69.2
 T4 53.6 41.7 to 65.2 58.0 47.6 to 67.8
Histologic grade
 Well/moderately differentiated 28.7 25.4 to 32.3 67.1 62.8 to 71.2
 Poorly/undifferentiated 27.3 20.2 to 35.7 61.2 53.7 to 68.2
 Unknown 37.6 24.2 to 53.2 65.0 49.8 to 77.6
Positive margins at surgery
 Yes 49.1 27.7 to 70.8 53.8 36.9 to 69.8
 No 28.3 24.7 to 32.2 66.5 62.8 to 69.9
 Unknown 24.7 17.4 to 33.9 62.2 47.1 to 75.3
* Proportions weighted by sampling fraction. Table excludes patients who did not undergo cancer-directed surgery (n = 20) or with missing or unknown chemothera-
py agents (n = 82); patients who received preoperative chemotherapy (n = 6) are included. CI = confidence interval; NA = not applicable; wt = weighted.











available online); however, the sequencing of radiation and 
chemotherapy differed by year of diagnosis (Table  5). The use 
of surgery followed by postoperative chemoradiation increased 
from 35.2% in 1990 or 1991 to 45.1% in 1995 and decreased 
from 2000 (41.6%) to 2010 (18.7%). The proportion of patients 
who received preoperative chemoradiation followed by surgery 
increased over the study period. From 2005 to 2010, the receipt 
of preoperative chemoradiation followed by surgery and post-
operative chemotherapy nearly doubled (11.2% in 2005 to 20.8% 
in 2010). Among chemotherapy treated patients (preoperative, 
postoperative, or both), the use of 5-FU alone decreased from 
38.3% in 1990 or 1991 to 10.3% in 2010, and there was an increase 
in the use of capectiabine alone (0.5% in 2000 to 20.8% in 
2010) (Table 5). Similarly, the proportion of patients who received 
FOLFOX increased from 2005 (32.3%) to 2010 (44.0%).
In the log-binomial regression models, being diagnosed 
in year 2000 (risk ratio [RR]  =  1.17, 95% confidence interval 
[CI] = 1.03 to 1.34), 2005 (RR = 1.26, 95% CI = 1.15 to 1.39), and 2010 
(RR = 1.24, 95% CI = 1.12 to 1.37) was associated with receipt of 
chemotherapy among stage III colon cancer patients compared 
with being diagnosed in 1990 or 1991 (Table 6). Increasing age 
(75–79 years: RR = 0.81, 95% CI = 0.71 to 0.91; ≥80 years: RR = 0.37, 
95% CI = 0.28 to 0.47), black (RR = 0.80, 95% CI = 0.71 to 0.91) and 
Hispanic (RR = 0.80, 95% CI = 0.67 to 0.97) race/ethnicity, and a 
Table 3. Receipt of select chemotherapy agents and combination chemotherapy among stage III colon cancer patients treated with adjuvant 













wt % wt % wt % wt % wt %
5-FU 98.8 99.9 96.9 88.6 79.3
Leucovorin 33.1 42.9 87.1 83.9 77.4
Levamisole 70.5 73.3 2.3 3.9 0.6
Bevacizumab † † † 16.1 6.3
Capecitabine † † 3.0 15.5 23.6
Cetuximab † † † 5.5 1.5
Irinotecan † † 8.0 10.1 6.1
Oxaliplatin † † 5.5 69.0 78.1
Other‡ 6.9 2.0 6.2 7.6 4.1
Chemotherapy regimen
5-FU alone 8.6 2.8 8.2 2.1 1.3
5-FU + leucovorin (only) 17.4 22.7 76.3 17.6 4.7
5-FU + levamisole (only) 56.4 53.3 0 0 0
FOLFOX (any) † † 5.5 62.9 72.6
FOLFIRI (any) † † 7.5 9.6 4.7
Capecitabine alone † † 0.2 3.6 12.1
CapeOx (only) † † 0 3.1 4.3
* Proportions weighted by sampling fraction and not mutually exclusive. 5-FU = 5-fluorouracil; CapeOx = capecitabine + oxaliplatin; FOLFIRI = 5-FU + leucovorin + 
irinotecan; FOLFOX = 5-FU + leucovorin + oxaliplatin; wt = weighted.
† No patient in our dataset received bevacizumab, cetuximab, capectiabine, irinotecan, or oxaliplatin in these years.
‡ Other includes less frequently administered chemotherapy agents, including methyl CCNU, CCNU, vincristine, PALA, UFT, methotrexate, and BCNU.
Figure 1. Proportion of stage III colon cancer patients diagnosed between 1990 and 2010 who received adjuvant chemotherapy by comorbidity score and age at diag-
nosis (n = 1849). Proportions weighted by sampling fraction. Figure excludes patients who did not undergo cancer-directed surgery (n = 9) or with missing or unknown 
chemotherapy agents (n = 82). Comorbidity score (CS) greater than 2 not shown for ages <55 and ≥80 years because of small number of observations (n < 5).











comorbidity score of 2 or greater (RR  =  0.56, 95% CI  =  0.35 to 
0.87) were associated with not receiving chemotherapy. Among 
stages II and III rectal cancer patients, being diagnosed in 1995 
(RR = 1.36, 95% CI = 1.17 to 1.58), 2000 (RR = 1.40, 95% CI = 1.19 
to 1.65), 2005 (RR = 1.40, 95% CI = 1.21 to 1.63) or 2010 (RR = 1.59, 
95% CI = 1.38 to 1.84) was associated with receipt of any chemo-
radiation (preoperative or postoperative) compared with being 
diagnosed in 1990 or 1991 (Table 6). Increasing age (65–74 years: 
RR  =  0.87, 95% CI  =  0.78 to 0.98; 75–79  years: RR  =  0.59, 95% 
CI = 0.47 to 0.74; ≥80 years: RR = 0.33, 95% CI = 0.25 to 0.45) was 
associated with not receiving chemoradiation.
Discussion
Our results demonstrate that receipt of adjuvant chemotherapy 
for colon cancer gradually increased starting in 1990, which 
coincides with the publication of major findings from large, 
randomized trials (4) and recommendations of the National 
Institutes of Health Consensus Conference (3). Consistent with 
guidelines (24–28), the majority of stage III patients in our study 
received chemotherapy, but there were some marked disparities 
by age and comorbidity. As noted by others, older patients and 
those with high comorbidity are less likely to receive chemo-
therapy (29–34). Some physicians may not endorse adjuvant 
therapy for select patients because the expected gains in over-
all survival do not outweigh the potential harms to quality of 
life. Older patients and those with multiple comorbidities may 
not wish to pursue aggressive treatment. Further, there may be 
uncertainty regarding appropriate treatment strategies for older 
patients because they have historically been excluded from clin-
ical trials (35).
Despite the uncertainty of evidence surrounding the use 
of adjuvant chemotherapy for stage II colon cancer, stage II 
patients frequently received chemotherapy during the study 
period. Almost one-third of all stage II patients, and more 
than 60% of younger patients (<55 years) with stage II disease, 
were treated with chemotherapy. These results are consist-
ent with other studies that suggest that a large proportion of 
stage II colon cancer patients receive chemotherapy (30,36–39) 
and that receipt differs by age and comorbidity (29,30,36,37). 
Although some early trials have suggested a similar reduction 
in risk of recurrence for stage II and III patients treated with 
chemotherapy (40–42), past and current guidelines recommend 
against chemotherapy for stage II disease (3,24–28), based on 
cumulative evidence from meta-analyses (9,43). The proportion 
of stage II patients treated with chemotherapy in our study may 
be a result of both overtreatment of normal-risk and appropriate 
treatment of high-risk patients. Stage II patients with high-risk 
features (eg, T4 tumors, poorly differentiated histology, lym-
phovascular invasion) can be considered for adjuvant therapy, 
and we observed a larger proportion of stage II patients with T4 
tumors or positive surgical margins treated with chemotherapy. 
However, only a small minority of stage II patients who received 
chemotherapy could be classified as high-risk. Our findings sup-
port the need for additional trials to identify subgroups of stage 
II colon cancer patients who are most likely to benefit from 
adjuvant chemotherapy.
Our results also highlight the rapid diffusion of newer 
therapies into community settings. Nearly 80% of all chem-
otherapy-treated patients with stage III colon cancer received 
oxaliplatin in 2010, compared with just 5% in 2000. This increase 
corresponds to a shift in evidence in favor of adding adjuvant 
oxaliplatin to 5-FU and its approval by the US Food and Drug 
Administration in 2004. Results of the Multicenter International 
Study of Oxaliplatin/5-Fluorouracil/Leucovorin (MOSAIC) trial 
showed an additional 23% reduction in risk of recurrence among 
patients treated with FOLFOX compared with those treated with 
5-FU and leucovorin alone (8,44). The increased use of oxaliplatin 
in our study also highlights contemporary controversy regarding 
the use of therapy in older patients. Although the MOSAIC trial 
and numerous other studies (45–48) support the use of oxalipl-
atin for stage III colon cancer, only a small proportion of patients 
enrolled in these trials were older than 70 years. More recently, 
studies suggest there is little or no survival benefit of adjuvant 
oxaliplatin for older patients (49,50), and current guidelines (25) 
recommend against routine use in these patients (>70  years). 
However, the increasing use of oxaliplatin observed in our study, 
combined with the findings of others (51), may suggest oxali-
platin is still widely used in this population subgroup. Because 
uncertainty remains regarding the role of oxaliplatin in older 
patients, careful consideration must be given to the potential 
survival benefit in conjunction with patient preferences, cost, 
and risk of adverse events.
Similarly, we observed an increase in the use of capecitabine, 
either alone or in combination with oxaliplatin, from 2000 
through 2010. Capecitabine was approved as an oral alternative 
Figure 2. Proportion of stages II and III rectal cancer patients who received preoperative or postoperative radiation therapy by year of diagnosis (n = 3016). Proportions 
weighted by sampling fraction. Figure excludes patients who did not undergo cancer-directed surgery (n = 145), received intraoperative radiation (n = 1), received both 
preoperative and postoperative radiation (n = 15), and those in whom a radiation sequence could not be determined (n = 13). XRT = radiation therapy.











to 5-FU after phase III trial data showed equivalent disease-
free survival, improved relapse-free survival, and fewer adverse 
events when comparing oral capecitabine to 5-FU and leucovorin 
(7). Our data provide support for a substitution effect, whereby 
the number of patients treated with capecitabine increased as 
the use of 5-FU simultaneously decreased. Capecitabine use 
has traditionally been difficult to measure on a population level 
because it is frequently underreported in Medicare claims data 
(52). This may be because claims data capture drug dispensing 
that generates a claim for reimbursement and do not capture 
information on prescribing. Differences between prescrib-
ing and dispensing may occur when patients decide not to fill 
the drug prescribed. One possibility is that patients with high 
copayments either do not fill capecitabine prescriptions (53) or 
receive the drug through pharmacy assistance programs, both 
of which are not captured in claims data. Given the limitations 
of administrative data sources, continuing to monitor treatment 
dispensing with capecitabine will likely remain a challenge. The 
unique features of our study design, particularly physician veri-
fication of therapy receipt, allowed us to provide a population-
based estimate of capecitabine use.
While adjuvant chemotherapy for stage III colon cancer has 
been universally recommended by guidelines since 1990, the 
sequence and combination of therapies for rectal cancer have 
evolved over time and are reflected in our analysis. The propor-
tion of patients who received preoperative radiation surpassed 
the proportion who received postoperative radiation in 2005. 
Also in 2005, patients treated with preoperative chemoradia-
tion (with or without postoperative chemotherapy) exceeded 
the proportion treated with postoperative chemoradiation. 
These changes parallel results of the landmark German trial 
published in 2004 (15) that showed preoperative chemoradiation 
decreased the risk of local recurrence, improved sphincter pres-
ervation, and decreased treatment-related toxicities compared 
with postoperative therapy. Although earlier trials (13,14,17) and 
treatment guidelines (24) advocated preoperative therapy to 
Table 4. Proportion of stages II and III rectal cancer patients who received preoperative or postoperative radiation therapy (n = 3016)*
Characteristics
Proportion of patients receiving therapy
Postoperative radiation Preoperative radiation
wt % 95% CI wt % 95% CI
Overall 31.6 29.1 to 34.1 27.3 24.7 to 30.0
Stage
 II 27.6 24.4 to 31.1 27.2 23.6 to 31.1
 III 34.8 31.2 to 38.5 27.3 23.7 to 31.2
Year of diagnosis
 1990/1991 42.7 39.3 to 46.2 2.8 1.7 to 4.5
 1995 51.3 46.4 to 56.3 4.6 2.9 to 7.2
 2000 45.3 37.3 to 53.4 14.4 10.4 to 19.6
 2005 26.3 21.5 to 31.8 33.8 27.9 to 40.4
 2010 18.8 14.6 to 23.9 47.3 41.7 to 52.9
Age at diagnosis, y
 <55 30.6 25.9 to 35.7 43.8 37.7 to 50.2
 55–64 36.1 30.4 to 42.1 29.9 24.9 to 35.5
 65–74 35.0 30.5 to 39.8 24.8 20.3 to 29.8
 75–79 30.4 23.3 to 38.6 15.7 10.0 to 23.9
 ≥80 18.6 12.8 to 26.2 6.5 3.8 to 10.8
Race/ethnicity
 White non-Hispanic 32.5 29.4 to 35.8 25.3 22.1 to 28.8
 Black non-Hispanic 31.0 26.4 to 36.0 29.7 25.1 to 34.7
 Hispanic 29.2 24.0 to 34.9 33.0 27.3 to 39.2
 Other 26.5 21.5 to 32.1 36.1 29.9 to 42.7
Health insurance
 Private/HMO/VA/Other 33.0 30.2 to 36.0 27.3 24.2 to 30.7
 Medicaid 25.5 18.6 to 33.8 36.0 28.2 to 44.6
 Medicare 27.5 21.3 to 34.6 22.0 15.7 to 29.9
 None 31.0 17.9 to 48.1 24.1 12.7 to 40.9
 Unknown 33.9 22.9 to 47.0 6.9 2.0 to 21.2
Comorbidity score
 0 31.3 28.4 to 34.4 29.1 25.8 to 32.5
 1 30.8 25.9 to 36.2 24.5 20.1 to 29.4
 ≥2 37.9 27.0 to 50.3 15.5 7.5 to 29.3
Chemotherapy†
 Yes 40.5 37.3 to 43.8 37.7 34.4 to 41.2
 No 10.2 8.0 to 12.9 1.8 1.1 to 2.9
 Unknown 6.6 2.8 to 14.6 5.9 2.1 to 15.1
* Proportions weighted by sampling fraction. Proportions combine across rows for total number of patients who received any radiation therapy. Table excludes pa-
tients who did not undergo cancer-directed surgery (n = 145), received intraoperative radiation (n = 1), received both preoperative and postoperative radiation (n = 17), 
and those in which a radiation sequence could not be determined (n = 13). CI = confidence interval; wt = weighted.
† Chemotherapy includes any chemotherapy received preoperatively, postoperatively, or both.











decrease the volume of the primary tumor, our results suggest 
that clinical practices did not shift toward preoperative treat-
ment until after 2000.
The large increase in the proportion of rectal cancer patients 
treated with preoperative chemoradiation followed by surgery 
and postoperative chemotherapy in our study reflects the con-
troversy surrounding the use of postoperative chemotherapy in 
this population. Although US guidelines advocate for the addi-
tion of postoperative chemotherapy to preoperative chemora-
diation and surgery (54,55), some randomized trials reported no 
survival benefit (56–59). Long-term results of the EORTC 22921 
trial suggested no difference in 10-year overall survival for 
patients treated with preoperative chemoradiation and postop-
erative chemotherapy compared with those treated with preop-
erative chemoradiation and surgery (56). However, a recent trial 
demonstrated improved disease-free survival with postoperative 
FOLFOX among rectal cancer patients treated with preoperative 
chemoradiation and surgery (60). Other studies (61,62) suggested 
that many rectal cancer patients treated with preoperative 
chemoradiation do not complete postoperative chemotherapy 
for reasons of age, performance status, pathological response, or 
surgical complications. Regardless of patient ability to tolerate 
additional therapy or response to preoperative treatment, the 
effect of postoperative chemotherapy remains unclear among 
patients previously treated with preoperative chemoradiation.
The differences we observed in the receipt of therapy for 
rectal cancer compared with colon cancer patients underscore 
inherent differences in the clinical behavior and treatment of 
these two distinct cancers. There was some difference in receipt 
of therapy by age and comorbidity for rectal cancer, but it was 
not as pronounced as the differences for colon cancer. For 
example, our results suggest a 30% difference in the proportion 
of stage III colon cancer patients with a comorbidity of 0 and 
greater than 2 who received chemotherapy compared with a 
difference of approximately 10% among rectal cancer patients 
receiving any radiation therapy. We also observed a lower receipt 
of adjuvant chemotherapy for black and Hispanic colon cancer 
patients compared with whites, but there was no racial dispar-
ity in chemoradiation receipt among rectal cancer patients. The 
modality of rectal cancer treatment changed frequently dur-
ing the study period, and differential receipt of therapy by race 
may have been masked by changing treatment paradigms. In 
addition, although colon and rectal cancer share many features, 
there is an increased risk of local recurrence among rectal can-
cer patients. Preventing recurrence is a primary goal of therapy, 
which may explain why a larger number of older, high comor-
bidity, and minority rectal cancer patients received therapy.
Our study has several strengths. Patients were sampled by 
tumor site, sex, and age and oversampled by race/ethnicity to 
ensure adequate sample sizes that supported analyses by a 
variety of covariates. Detailed treatment information was avail-
able, including specific chemotherapy agents and treatment 
dates, which were verified by treating physicians and/or medical 
record review. Our results also complement randomized studies 
of treatment efficacy by demonstrating how changes in com-
munity practice have paralleled shifts in evidence from clinical 
trials.
A limitation of our analysis is the inability to fully explain 
trends and patterns of care observed during the study period 
that may be because of patient preferences or changes in health-
care delivery. For example, there was an overall decrease in the 
receipt of therapy among both colon and rectal cancer patients 
in 2010 that is likely not a result of differences in patient age or 
comorbidity. The decrease in therapy may instead be because 
of the increasing costs of CRC care (53,63–67) and the impact of 
the 2008 economic recession (eg, changes in insurance coverage, 
Table 5. Sequence of therapy and receipt of select chemotherapy agents among stages II and III rectal cancer patients by year of diagnosis 













wt % wt % wt % wt % wt %
Surgery alone 38.8 30.4 24.4 20.1 18.5
Surgery + postoperative radiation 7.0 4.7 3.0 2.2 0.3
Surgery + postoperative chemotherapy 12.5 12.2 14.3 17.8 13.6
Surgery + postoperative chemoradiation 35.2 45.1 41.6 24.2 18.7
Preoperative chemoradiation + surgery 0.9 3.8 13.3 22.8 24.2
Preoperative chemoradiation + surgery + postoperative chemotherapy † † † 11.2 20.8
Chemotherapy agents‡
5-FU alone 38.3 35.3 35.8 16.5 10.3
5-FU + leucovorin (only) 23.3 31.5 53.9 14.3 3.5
5-FU + levamisole (only) 25.3 14.9 1.1 0 0
FOLFOX (any) † † 0 32.3 44.0
FOLFIRI (any) † † 5.1 3.3 6.3
Capecitabine alone † † 0.5 10.7 20.8
CapeOx (only) † † 0 6.1 5.9
* Proportions weighted by sampling fraction. Percentages do not add to 100 because of infrequently administered treatment sequences (eg, preoperative radiation + 
surgery). Table excludes patients who did not undergo cancer-directed surgery (n = 145) and with unknown or missing chemotherapy agents (n = 47). Patients with 
unknown or missing dates of chemotherapy or surgery (n = 25) and unknown radiation and surgery sequence (n = 9) are excluded from the proportions of therapy 
sequences, including chemotherapy or radiation. 5-FU = 5-fluorouracil; CapeOx = capecitabine + oxaliplatin; FOLFIRI = 5-FU + leucovorin + irinotecan; FOLFOX = 5-FU 
+ leucovorin + oxaliplatin; wt = weighted.
† Preoperative chemoradiation + surgery + postoperative chemotherapy not measured, and no patient in our dataset received FOLFOX, FOLFIRI, capecitabine, and 
CapeOx in these years.
‡ Chemotherapy agents limited to patients who received any chemotherapy (n = 2039) and include chemotherapy delivered preoperatively, postoperatively, or both.











copays, or cost sharing), which are not captured in the data. We 
also did not have a measure of performance status. Comorbidity 
score may account for some of the differences we observed in 
receipt of therapy, but performance status may further explain 
these differences. Finally, rates of physician verification were 
lower in 1990 or 1991 and 1995 than in other study years. We 
considered patients for whom therapy was recommended but it 
was unknown whether therapy was received as having received 
treatment in the analysis. Although there were few of these 
cases, our results may be slightly overestimated.
In summary, multiple randomized trials have demonstrated 
the efficacy of adjuvant therapies in improving the overall and 
disease-free survival of patients with locally advanced colo-
rectal cancer. Our findings demonstrate increased adoption of 
adjuvant therapies for both colon and rectal cancer patients and 
differences in receipt of therapy by age, comorbidity, and year 
of diagnosis. Ongoing use of these therapies in community set-
tings is critical to further reducing CRC mortality.
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